Denise Cristiana Faro

Dr. Denise Cristiana Faro

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2023 in JACC
Verified
Journal Article
Closed access
AGAntonio Greco
Antonio Greco
GOGiovanni Occhipinti
Giovanni Occhipinti
DGDaniele Giacoppo
Daniele Giacoppo
FAFederica Agnello
Federica Agnello
CLClaudio Laudani
Claudio Laudani
DCDavide Capodanno
Davide Capodanno

9 October 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
DFDenise Cristiana Faro
Denise Cristiana Faro
CLClaudio Laudani
Claudio Laudani
FAFederica Giuseppa Agnello
Federica Giuseppa Agnello
NANicola Ammirabile
Nicola Ammirabile
SFSimone Finocchiaro
Simone Finocchiaro
DCDavide Capodanno
Davide Capodanno

6 October 2025 in JACC
Verified
Journal Article
Open access
AIAntonino Imbesi
Antonino Imbesi
AGAntonio Greco
Antonio Greco
MSMarco Spagnolo
Marco Spagnolo
CLClaudio Laudani
Claudio Laudani
CRCarmelo Raffo
Carmelo Raffo
DCDavide Capodanno
Davide Capodanno
Despite advances in secondary prevention, adverse cardiovascular events still occur after acute myocardial infarction (AMI). Contributing to residual cardiovascular risk, acute and persistent inflammation is a stronger predictor of recurrent events and mortality than low-density lipoprotein cholesterol. The inflammatory response following AMI is a finely regulated, multiphase process, beginning with a proinflammatory phase followed by a reparative phase. Disruptions in its regulation lead to persistent low-grade inflammation and worse clinical outcomes. Modulating inflammation has emerged as a promising secondary prevention strategy, with several drugs being tested with conflicting results regarding their efficacy and safety. Recently, novel approaches have reignited the interest in anti-inflammatory strategies after AMI. However, key knowledge gaps remain regarding potential class effects, drug choice, patient selection, and the optimal administration timing. This review provides an updated and comprehensive overview of inflammatory mechanisms after AMI and critically appraises the evolving clinical evidence surrounding anti-inflammatory therapies for secondary cardiovascular prevention.

Verified
Journal Article
Open access
PDF file
DFDenise Cristiana Faro
Denise Cristiana Faro
FPFrancesco Lorenzo Di Pino
Francesco Lorenzo Di Pino
IMInes Monte
Ines Monte
Anderson-Fabry disease (AFD), a genetic disorder caused by mutations in the α-galactosidase-A (GLA) gene, disrupts lysosomal function, leading to vascular complications. The accumulation of globotriaosylceramide (Gb3) in arterial walls triggers upregulation of adhesion molecules, decreases endothelial nitric oxide synthesis, and induces reactive oxygen species production. This cascade results in fibrotic thickening, endothelial dysfunction, hypercontractility, vasospasm, and a pro-thrombotic phenotype. AFD patients display increased intima-media thickness (IMT) and reduced flow-mediated dilation (FMD), indicating heightened cardiovascular risk. Nailfold capillaroscopy (NFC) shows promise in diagnosing and monitoring microcirculatory disorders in AFD, though it remains underexplored. Morphological evidence of AFD as a storage disorder can be demonstrated through electron microscopy and immunodetection of Gb3. Secondary pathophysiological disturbances at cellular, tissue, and organ levels contribute to the clinical manifestations, with prominent lysosomal inclusions observed in vascular, cardiac, renal, and neuronal cells. Chronic accumulation of Gb3 represents a state of ongoing toxicity, leading to increased cell turnover, particularly in vascular endothelial cells. AFD-related vascular pathology includes increased renin-angiotensin system activation, endothelial dysfunction, and smooth muscle cell proliferation, resulting in IMT increase. Furthermore, microvascular alterations, such as atypical capillaries observed through NFC, suggest early microvascular involvement. This review aims to unravel the complex interplay between inflammation, oxidative stress, and endothelial dysfunction in AFD, highlighting the potential connections between metabolic disturbances, oxidative stress, inflammation, and fibrosis in vascular and cardiac complications. By exploring novel cardiovascular risk factors and potential diagnostic tools, we can advance our understanding of these mechanisms, which extend beyond sphingolipid accumulation to include other significant contributors to disease pathogenesis. This comprehensive approach can pave the way for innovative therapeutic strategies and improved patient outcomes.

Verified
Journal Article
Open access
PDF file
IMInes Monte
Ines Monte
DFDenise Cristiana Faro
Denise Cristiana Faro
Giancarlo TrimarchiGiancarlo Trimarchi
Giancarlo Trimarchi
FGFabrizio De Gaetano
Fabrizio De Gaetano
MCMariapaola Campisi
Mariapaola Campisi
Cesare de GregorioCesare de Gregorio
Cesare de Gregorio
Background: Left atrial (LA) function is crucial for assessing left ventricular filling in various cardiovascular conditions. Cardiac Amyloidosis (CA) is characterized by atrial myopathy and LA function impairment, with diastolic dysfunction up to restrictive filling pattern, leading to progressive heart failure and arrhythmias. This study evaluates LA function and deformation using speckle tracking echocardiography (STE) in patients with CA compared to a cohort of patients with sarcomeric Hypertrophic Cardiomyopathy (HCM) and a control group. Methods: We conducted a retrospective, observational study (from January 2019 to December 2022) including a total of 100 patients: 33 with ATTR-CA, 34 with HCMs, and 33 controls. Clinical evaluation, electrocardiograms, and transthoracic echocardiography were performed. Echocardiogram images were analyzed in post-processing using EchoPac software for LA strain quantification, including LA-reservoir, LA-conduit, and LA-contraction strain. Results: The CA group exhibited significantly impaired LA function compared to HCMs and control groups, with LA-reservoir median values of −9%, LA-conduit −6.7%, and LA-contraction −3%; this impairment was consistent even in the CA subgroup with preserved ejection fraction. LA strain parameters correlated with LV mass index, LA volume index, E/e’, and LV-global longitudinal strain and were found to be associated with atrial fibrillation and exertional dyspnea. Conclusions: LA function assessed by STE is significantly impaired in CA patients compared to HCMs patients and healthy controls. These findings highlight the potential supportive role of STE in the early detection and management of the disease.

9 January 2024 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
GOGiovanni Occhipinti
Giovanni Occhipinti
CLClaudio Laudani
Claudio Laudani
MSMarco Spagnolo
Marco Spagnolo
SFSimone Finocchiaro
Simone Finocchiaro
PMPlacido Maria Mazzone
Placido Maria Mazzone
DCDavide Capodanno
Davide Capodanno
The evolution of anticoagulation therapy, from vitamin K antagonists to the advent of direct oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite improved safety demonstrated in pivotal trials and post-marketing observations, persistent concerns exist, particularly regarding bleeding risk and the absence of therapeutic indications in specific subgroups or clinical contexts. Factor XI (FXI) has recently emerged as a pivotal contributor to intraluminal thrombus formation and growth, playing a limited role in sealing vessel wall injuries. Inhibiting FXI presents an opportunity to decouple thrombosis from haemostasis, addressing concerns related to bleeding events while safeguarding against thromboembolic events. Notably, FXI inhibition holds promise for patients with end-stage renal disease or cancer, where clear indications for DOACs are currently lacking. Various compounds have undergone design, testing, and progression to phase 2 clinical trials, demonstrating a generally favourable safety and tolerability profile. However, validation through large-scale phase 3 trials with sufficient power to assess both safety and efficacy outcomes is needed. This review comprehensively examines FXI inhibitors, delving into individual classes, exploring their pharmacological properties, evaluating the latest evidence from randomized trials, and offering insights into future perspectives.